Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | -1.04% | -4.28% | -4.04% |
May. 09 | Transcript : ProQR Therapeutics N.V. - Special Call | |
May. 09 | ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 18.04M | Sales 2025 * | 18.17M | Capitalization | 157M |
---|---|---|---|---|---|
Net income 2024 * | -37M | Net income 2025 * | -33M | EV / Sales 2024 * | 8.69 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.63 x |
P/E ratio 2024 * |
-4.45
x | P/E ratio 2025 * |
-4.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.34% |
Latest transcript on ProQR Therapeutics N.V.
1 day | -1.03% | ||
1 week | -3.03% | ||
Current month | -1.03% | ||
1 month | -3.52% | ||
3 months | +1.05% | ||
6 months | +27.15% | ||
Current year | -3.03% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel de Boer
CEO | Chief Executive Officer | 41 | 12-02-20 |
Founder | 60 | 12-02-20 | |
Jurriaan Dekkers
DFI | Director of Finance/CFO | - | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Domenico Valerio
FOU | Founder | 67 | 12-02-20 |
Founder | 60 | 12-02-20 | |
Alison Lawton
BRD | Director/Board Member | 62 | 14-09-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 1.9 | -1.04% | 61 656 |
24-05-20 | 1.92 | -1.03% | 42,498 |
24-05-17 | 1.94 | +1.04% | 64,262 |
24-05-16 | 1.92 | +0.52% | 56,461 |
24-05-15 | 1.91 | -3.78% | 120,844 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.03% | 157M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.55% | 21.6B | |
-12.38% | 22.31B | |
-6.77% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- PRQR Stock